{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.1","upperLimit":"98.6","value":"95.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"}],"units":"Participants"}],"description":"Assess concordance of genomic alterations in ALK (EML4-ALK fusions) detected in plasma (using the OncotypeSEQ Liquid Select assay) versus tumor tissue (assessed centrally using FoundationOne OR locally based on the patient's clinic) in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib).","id":"OG000","title":"Patients With Non-squamous NSCLC Either Newly Diagnosed or Pro"}],"paramType":"NUMBER","populationDescription":"Subjects who received ALK (EML4-ALK fusion) mutation testing on both their tissue and plasma samples.","reportingStatus":"POSTED","timeFrame":"Time between patient tumor tissue biopsy and and blood collection, up to 8 weeks","title":"Concordance of Genomic Alterations in ALK (EML4-ALK Fusions) Detected in Plasma Versus Tumor Tissue.","type":"SECONDARY","unitOfMeasure":"Overall percent agreement (OPA)"}